Can We Really Use ß-Lactam/ß-Lactam Inhibitor Combinations for the Treatment of Infections Caused by Extended-Spectrum ß-Lactamase–Producing Bacteria?

As clinicians, we readily appreciate that this study has significant implications for our daily practice. These findings challenge us to revisit a fundamental therapeutic approach against antibioticresistant bacteria and reward us with a needed alternative to carbapenems for the treatment of ESBL-producing E. coli bloodstream infections. Beyond that, this study may herald a renaissance of BLBLI therapy in the era of ‘‘bad bugs, no drugs.’’ For years, the paradigm of how to treat